Patients are now being recruited into a randomized, multicenter trial--the kind that the FDA demands before a drug can be approved.

FORBES: The Man Behind Millennium's Cancer Drug

The research with CDX-110 is further along, but results from the first multicenter trial will not be made public until later this spring.

CNN: Vaccine may shift odds against deadly brain cancer